nivalin 5 mg/ml šķīdums injekcijām
sopharma ad, bulgaria - galantamīna hidrobromīds - Šķīdums injekcijām - 5 mg/ml
nivalin 2,5 mg/ml šķīdums injekcijām
sopharma ad, bulgaria - galantamīna hidrobromīds - Šķīdums injekcijām - 2,5 mg/ml
pamitor 15 mg/ml koncentrāts infūziju šķīduma pagatavošanai
chiesi pharmaceuticals gmbh, austria - dinātrija pamidronāts - koncentrāts infūziju šķīduma pagatavošanai - 15 mg/ml
anaprilīns 10 mg tabletes
olainfarm, as, latvia - propranolola hidrohlorīds - tablete - 10 mg
lysthenon 20 mg/ml šķīdums injekcijām
takeda austria gmbh, austria - suksametonija hlorīds - Šķīdums injekcijām - 20 mg/ml
anaprilīns 40 mg tabletes
olainfarm, as, latvia - propranolola hidrohlorīds - tablete - 40 mg
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - zāles obstruktīvu elpceļu slimību, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
brimica genuair
covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - plaušu slimība, hroniska obstruktīva - zāles obstruktīvu elpceļu slimību, - brimica genuair ir indicēts kā uzturējoša bronhodilatatora terapija gaisa plūsmas obstrukcijai un simptomu atvieglošanai pieaugušiem pacientiem ar hronisku obstruktīvu plaušu slimību (hops).
duaklir genuair
covis pharma europe b.v. - aclidinium bromīds, formoterol fumarate dihidrāts - plaušu slimība, hroniska obstruktīva - zāles obstruktīvu elpceļu slimību, - duakliru genuair ir indicēts kā uzturēšanas bronhodilatatora terapija simptomu mazināšanai pieaugušiem pacientiem ar hronisku obstruktīvu plaušu slimību (hops).
duoresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - zāles obstruktīvu elpceļu slimību, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).